Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JUNEL FE 1.5/30 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive; suppresses gonadotropin release (FSH, LH) via negative feedback, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years who desire contraception and have not responded to topical therapy)
Prevention of pregnancy (FDA-approved)
One tablet orally once daily, each tablet containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg, taken at the same time each day for 21 days followed by 7 days of placebo (iron tablets).
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norethindrone: 6-12 hours (terminal, multidose); ethinyl estradiol: 12-18 hours (terminal). Clinical context: Steady-state achieved within 5-7 days; missed doses may reduce contraceptive efficacy.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol: primarily metabolized via CYP3A4; norethindrone: primarily reduced and conjugated, with CYP3A4 involvement.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: 30-50% (norethindrone metabolites), 20-40% (ethinyl estradiol metabolites); biliary/fecal: 20-30% (norethindrone), 30-50% (ethinyl estradiol). Conjugated metabolites excreted in bile and undergo enterohepatic recirculation.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethindrone: 60-80% bound to albumin and SHBG; ethinyl estradiol: ~98% bound to albumin (specific binding to SHBG not significant).
~99% bound to serum albumin and sex hormone-binding globulin.
Norethindrone: 2-4 L/kg; ethinyl estradiol: 5-10 L/kg. Clinical meaning: Indicates extensive tissue distribution and slow clearance; Vd may increase in obesity.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: Norethindrone ~60-70% (first-pass metabolism); ethinyl estradiol ~40-50% (presystemic conjugation in gut and liver).
Oral: ~70% due to first-pass metabolism.
No specific dose adjustment provided in labeling; use with caution in patients with renal impairment. GFR-based modifications not established.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in patients with hepatic impairment (Child-Pugh class B or C) or active liver disease. No specific dose adjustment for mild impairment; use with caution.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. In post-menarche adolescents, dosing is the same as adults: one tablet daily for 21 days, then 7 days placebo.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women; no specific geriatric dosing considerations.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women >35 years) and with number of cigarettes smoked. Women >35 years who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders (e.g., DVT, PE, stroke, MI),Hepatic neoplasia risk,Liver disease (e.g., jaundice, hepatitis),Elevated blood pressure,Gallbladder disease,Carbohydrate/lipid metabolic effects,Ocular lesions (e.g., retinal thrombosis),Menstrual irregularities/breakthrough bleeding,Use in pregnancy (should be ruled out before initiation),Depression
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Hypersensitivity to any component,Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Known or suspected breast cancer or other estrogen-sensitive neoplasia,Benign or malignant liver tumor (current or history),Hepatic adenoma or carcinomas,Active liver disease with abnormal function tests,Major surgery with prolonged immobilization,Diabetes with vascular involvement,Uncontrolled hypertension,Migraine with focal neurological symptoms (current or history),Smoking in women >35 years
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food interactions are reported. However, grapefruit juice may increase ethinyl estradiol levels but interaction is considered weak; avoid excessive grapefruit juice consumption. Ferrous fumarate may reduce absorption of tetracycline antibiotics if taken together; space doses by at least 2 hours. No dietary restrictions are required.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
First trimester: Inadvertent use does not increase risk of major birth defects. Second and third trimesters: Avoid use due to risk of fetal harm from estrogenic and progestogenic effects, including potential genitourinary tract abnormalities. Postnatal effects: Possible long-term neurodevelopmental impacts reported in animal studies.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted in breast milk in small amounts; M/P ratio for ethinyl estradiol approximately 0.04–0.30. Progestin M/P ratio variable. May reduce milk production and quality. Use only if necessary and with caution, especially in early postpartum period.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated during pregnancy; no dose adjustment exists. Discontinue immediately if pregnancy occurs. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are not applicable as drug is not used.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Junel Fe 1.5/30 is a combination oral contraceptive containing ethinyl estradiol 30 mcg and norethindrone 1.5 mg, with ferrous fumarate as placebo. Consider starting on first day of menses or first Sunday after onset. Missed pills increase pregnancy risk; if missing one pill, take as soon as remembered. For missed two pills in week 1 or 2, take two pills daily for two days and use backup contraception. If missed in week 3, consider finishing current pack and skipping placebo, or starting new pack the next day. Drug interactions include rifampin, certain anticonvulsants, and St. John's wort, which may reduce efficacy. Monitor for DVT, PE, stroke, and MI, especially in smokers over 35, hypertensive, diabetic, or obese patients.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time; do not skip days.,If you miss a pill, refer to the package instructions or ask your healthcare provider.,Use backup contraception (e.g., condoms) if you miss pills or start late.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek emergency care for severe abdominal pain, chest pain, leg swelling, or vision changes.,Smoking increases risk of serious cardiovascular effects; avoid smoking, especially if over 35.,Iron supplements are included; ferrous fumarate in placebo tablets is not effective for contraception.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JUNEL FE 1.5/30 vs AFIRMELLE, answered by our medical review team.
JUNEL FE 1.5/30 is a Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropin release (FSH, LH) via negative feedback, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JUNEL FE 1.5/30 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JUNEL FE 1.5/30 is: One tablet orally once daily, each tablet containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg, taken at the same time each day for 21 days followed by 7 days of placebo (iron tablets).. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JUNEL FE 1.5/30 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JUNEL FE 1.5/30 is classified as Category C. First trimester: Inadvertent use does not increase risk of major birth defects. Second and third trimesters: Avoid use due to risk of fetal harm from estrogenic and progestogenic e. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.